{"id":"NCT01243450","sponsor":"Spear Pharmaceuticals","briefTitle":"Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo","officialTitle":"Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2010-11-18","resultsPosted":"2014-11-18","lastUpdate":"2020-01-03"},"enrollment":958,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne"],"interventions":[{"type":"DRUG","name":"Tretinoin","otherNames":["active medication"]},{"type":"DRUG","name":"placebo","otherNames":["inactive medication"]}],"arms":[{"label":"Active generic","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Brand","type":"ACTIVE_COMPARATOR"}],"summary":"The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.","primaryOutcome":{"measure":"Acne Lesion Percent Reduction","timeFrame":"12 week","effectByArm":[{"arm":"Active Generic","deltaMin":-54.3,"sd":10},{"arm":"Placebo","deltaMin":-35,"sd":8},{"arm":"Brand","deltaMin":-53.5,"sd":10}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":8,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":401},"commonTop":[]}}